Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Optimer Fires Execs For Questionable Financial Practices

This article was originally published in The Pink Sheet Daily

Executive Summary

A year after FDA approval of its antibiotic Dificid, the Optimer board has ousted its chairman and at least two other top executives.

You may also be interested in...

Optimer's Early Sales Of Dificid Topping Analyst Projections

The anti-clostridial antibiotic, approved by FDA in May, is seeing rapid early adoption by hospital formularies.

Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas

Phase III data showing an improved relapse rate relative to the standard of care drove the deal, which could be worth up to $214 million.

Optimer Pharmaceuticals Inc.

The company is developing an easy to use platform technology for the rapid assembly of single-chain, straight-branched oligosaccharides--a rational design appproach to carbohydrate drug discovery.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts